In the BioHarmony Drug Report Database
Prolixin Decanoate (fluphenazine decanoate) is a small molecule pharmaceutical. Fluphenazine decanoate was first approved as Prolixin Decanoate on 1982-01-01. It is used to treat psychotic disorders and schizophrenia in the USA. It is known to target D(2) dopamine receptor, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 7, D(1B) dopamine receptor, histamine H1 receptor, D(1A) dopamine receptor, and 5-hydroxytryptamine receptor 2A.
Image (chem structure or protein)